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Rheumatoid	 arthritis	 (RA)	 is	 an	 autoimmune	 disease	 affecting	 joints	 due	 to	 the	 persistent	
inflammation	 of	 the	 synovial	 tissue.	 It	 affects	 1%	 of	 the	 worldwide	 population	 with	 high	
socioeconomic	costs.	Patients	usually	require	lifetime	treatments	in	order	to	prevent	late	stage	
of	the	disease,	which	leads	to	a	condition	of	disability	and	pain.	Despite	the	introduction	of	
biological	 drugs,	 Methotrexate	 (MTX)	 is	 still	 the	 gold	 standard.	 However,	 it	 shows	 some	
weakness	such	as	inefficacy	or	adverse	events	after	long	term	usage.	For	this	reason,	there	is	
the	need	to	develop	drugs	with	an	 improved	safety	profile	and	higher	therapeutic	efficacy.	































































































































































































































































































































Rheumatoid	 arthritis	 (RA)	 is	 a	 systemic	 autoimmune	disease	 (Firestein	 2003)(Smolen	 et	 al.	
2007)	characterized	by	the	chronic	inflammation	of	joint	and	bone	destruction	(Aletaha	et	al.	
2010)(Smolen	 et	 al.	 2016).	 Despite	 new	 therapies	 improve	 patients’	 outcomes	 with	 RA,	





found	 in	 palaeopathological	 specimens	 in	 Native	 American	 tribes	 in	 North	 America	 (19).	
Interestingly,	 in	 these	 regions	 the	 incidence	 of	 RA	 remains	 really	 high	with	 5%	 of	 disease	

















































environmental	 factors	 and	 genetic	 predisposition	 increase	 the	 probability	 to	 develop	 RA	
(McInnes	&	Schett	2011a).	Usually,	patients	are	divided	 into	 seropositive	and	 seronegative	







is	 less	 well	 understood	 compared	 to	 the	 seropositive,	 probably	 because	 of	 a	 lack	 of	






very	 interesting	 epidemiological	 studies,	 linking	 the	 genetic	 features	 to	 the	 pathology,	

























































al.	 2009).	 Moreover,	 this	 bacterium	 has	 its	 own	 PAD	 enzyme	 able	 to	 switch	 arginine	 in	
citrulline.	For	this	reason,	a	model	of	molecular	mimicry	has	been	hypothesized.	According	to	
this	model,	when	the	immune	system	reacts	against	P.	Gingivalis	infection,	antibodies	against	









proteins	 post-translational	 modifications	 such	 as	 acetylation,	 methylation	 and	
phosphorylation.	 These	 processes	 lead	 to	 a	 very	 complex	 network	where	 genes	 are	 finely	




methylation	 signature	 of	 genes	 encoding	 the	 JACK-STAT	 pathway,	 explaining,	 partly,	 the	
different	 degree	 of	 inflammation	 between	 joints	 (Ai	 et	 al.	 2016).	 Another	 mechanism	 of	
epigenetic	regulation	is	represented	by	many	microRNAs.	They	can	target	mRNAs	leading	to	




environmental	 factors,	 a	 characteristic	 genotype,	 post-translational	modification	 and	other	
kinds	of	gene	expression	regulations	contribute	to	the	onset	of	the	disease.	According	to	one	




(Malmström	 et	 al.	 2016)	 during	 the	 development	 of	 the	 pathology,	 there	 are	 four	 phases	
(Figure	2).	The	first	phase	is	called	"triggering".	At	this	stage,	the	mucosal	surfaces,	such	as	the	
lining	 of	 the	 lungs,	 gums	 and	 intestinal	 mucosa,	 together	 with	 environmental	 stimuli	 and	
genetic	risk	factors	trigger	the	immune	response	against	self-peptides.	In	the	second	phase,	
called	 “maturation”,	 the	 immune	 system	matures	 and	 spreads	 its	 epitopes,	 enhancing	 the	
antibody	titre	of	RF	and	ACPA.	This	 immune	response	does	not	occur	 in	 the	 joints	but	 into	
lymph	 nodes	 and/or	 into	 other	 secondary	 lymphoid	 tissue	 where	 T-cells	 and	 B-cells	 are	
activated	and	proliferate.	The	third	phase	called	“targeting”	is	characterized	by	the	presence	
of	 the	 clinical	 signs,	 such	as	bone	 loss	and	 joint	pain.	 Specifically,	ACPAs	may	directly	bind	
osteoclasts,	which	 in	 response	produce	C-X-C	Motif	Chemokine	Ligand	8	 (CXCL8)	known	as	
interleukin	8	(IL8).	It	can	acts	as	growth	factor	for	osteoclasts	or	as	pain	inducer	when	it	binds	
their	 receptors,	 C-X-C	 Motif	 Chemokine	 receptor	 1	 (CXCR1)	 and	 CXCR2,	 expressed	 on	
nociceptive	nerves.	The	last	phase,	called	“fulminant	disease”,	is	characterized	by	the	synovitis.	
Indeed,	 ACPAs	 can	 bind	 citrullinated	 histones	 causing	 the	 neutrophil	 extracellular	 traps	
(NETosis).	Moreover,	other	citrullinated	proteins	can	be	bound	by	Toll-like	receptors	 (TRLs)	
expressed	on	synovial	cells	and	APCs,	which	in	turn	produce	pro-inflammatory	cytokines	like	
tumor	 necrosis	 factor	 (TNF),	 interleukin-6	 (IL-6)	 and	 matrix	 metalloproteinases	 (MMPs),	
responsible	 for	 the	 cartilage	 and	 bone	 destruction.	 According	 to	 this	 model,	 the	 immune	
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with	 early	 ACPA-positive	 RA	 presented	 macroscopic	 and	 microscopic	 changes,	 such	 as	
inflammatory	 cells	 infiltration,	 of	 the	 lung	mucosa,	 whereas	 seronegative	 RA	 patients	 and	
healthy	 individuals	 do	 not	 show	 any	 changes	 (Reynisdottir	 et	 al.	 2014).	 Another	work	 has	







that	 antigen	 presenting	 cells	 (APCs),	 like	 dendritic	 cells,	 macrophages	 and	 B-cells,	 locally	
activated	by	neo-citrullinated	antigens	may	trigger	T-cell	mediated	immunity	(Figure	3).	
However,	since	not	all	seropositive	patients	with	RA	present	inflammation	or	changes	in	the	
lung	mucosa,	 possibly	 other	 tissues	 are	 able	 to	 trigger	 the	 first	 immune	 response.	 Among	







sC5b-9	and	the	cleavage	 fragments	Bb,	were	 increased	several	 times	 (Brodeur	et	al.	1991).	
ACPA	and	RF	may	interact	with	antigens	present	in	the	joints	forming	immune	complexes	able	
to	activate	the	local	complement	(Suwannalai	et	al.	2014).	Other	molecules,	released	from	the	
extracellular	matrix	 of	 cartilage	 or	materials	 from	 dead	 cells,	 can	 trigger	 the	 complement	
activation	thus	suggesting	that	the	complement	system	has	a	role	in	both	early	phase	and	late	
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generated	 by	 the	 paracrine/autocrine	 effects	 of	 these	 factors,	 leads	 to	 a	 perpetual	
inflammation.	Indeed,	the	inflamed	hyperplastic	synovial	tissue	at	the	cartilage-bone	interface,	
called	 pannus,	 behaves	 like	 a	 locally	 invasive	 tumor,	 where	 activated	 FLS,	 macrophages,	
osteoclasts	and	lymphocytes	are	able	to	destroy	and	infiltrate	the	lining	layer	and	the	cartilage	
(Bartok	 &	 Firestein	 2011).	 The	 FLS	 proliferation	 is	 stimulated	 by	 growth	 factors	 like	 basic	
fibroblast	growth	 factor	 (bFGF)	 (Melnyk	et	al.	1990),	platelet-derived	growth	 factor	 (PDGF)	
(Mor	et	al.	2005)	and	transforming	growth	factor-beta	(TGF-beta)	(Allen	et	al.	1990),	released	
by	 leukocytes.	 Moreover,	 the	 FLS	 apoptosis	 rate	 is	 decreased,	 probably	 because	 of	 p53	
mutation	(Firestein	et	al.	1997),	B-cell	lymphoma	2	(Bcl-2)	overexpression	(Perlman	et	al.	2000)	
or	Fas	ligand	(FasL)	dysregulation	(Perlman	et	al.	2001).	The	FLS	have	a	primary	role	in	cartilage	
invasion	 and	 degradation,	 indeed	 they	 secrete	 a	 broad	 set	 of	 MMPs	 responsible	 for	 this	
process.	In	particular,	during	the	disease,	FLS	stimulated	with	IL-1,	TNF-beta	and	growth	factors	





pro-angiogenetic	 factors	 are	 produced.	 Among	 these,	 vascular	 endothelial	 growth	 factor	
(VEGF)	 (Cho	 et	 al.	 2002),	 fibroblast	 growth	 factor-2	 (FGF-2)	 (Yamashita	 et	 al.	 2002)	 and	
interleukin-18	(IL-18)	(Morel	et	al.	2002)	contribute	to	the	inflammatory	process	and	pannus	







colony-stimulating	 factor	 (M-CSF)	 and	 the	 receptor	 activator	 of	 NF-κB	 ligand	 (RANKL)	 are	
principally	responsible	for	the	osteoclasts	survival,	activation	and	differentiation	(Glantschnig	





these	 cytokines	 were	 effective	 for	 the	 prevention	 of	 bone	 destruction	 (McInnes	 &	 Schett	
2011).		
1.1.8. Adaptive	immunity	
It	 is	 known	 that	 adaptive	 immunity	 has	 a	 pivotal	 role	 in	 the	 pathogenesis	 of	 rheumatoid	
arthritis.	 In	 particular,	 T-cells	 (CD4+)	 are	 activated	 through	 the	 interaction	 with	 antigenic	


































migration	 from	 the	 bone	marrow	 to	 the	 inflamed	 tissue	 (Cornish	 et	 al.	 2009).	Mast	 cells,	
activated	by	TLR,	Fc	receptors	g	or	Fc	receptors	e	produce	cytokines,	chemokines,	proteases	

















Neoangiogenesis,	 as	 already	 mentioned,	 is	 a	 physiological	 process,	 however	 it	 plays	 an	
important	 role	 in	 several	 pathological	 processes.	 Usually,	 damaged	 tissues	 face	 hypoxic	
conditions	 which,	 in	 turn,	 promotes	 the	 formation	 of	 new	 vessels	 in	 order	 to	 restore	 the	






phenotype,	moreover,	due	to	the	huge	 leukocytes	 infiltration,	there	 is	an	 increased	oxygen	
consumption.	Different	studies	have	demonstrated	that	VEGF,	pro-inflammatory	cytokines	like	
IL-6	 and	 matrix	 metalloproteinases	 expression	 (MMP1	 and	 MMP3)	 are	 associated	 to	 the	
hypoxia	inducible	factors	(HIF)	activation	(Lu	&	Kang	2010)(Ahn	et	al.	2008).	Therefore,	hypoxia	





vessels	which	 promotes	 inflammation	 of	 the	 synovial	membrane.	 One	 of	 the	most	 potent	
chemokines	 is	 the	 CXCL12,	 also	 called	 stromal	 cell-derived,	 which	 is	 overexpressed	 in	
inflammatory	disease.	Its	receptor	CXCR4	is	expressed	by	hemopoietic	stem	cells,	monocytes	
and	lymphocytes	and	exerts	a	homing	function.	CXCL12-CXCR4	system	is	strongly	implicated	











of	 the	 avb3	 reduced	 neoangiogenesis,	 cell	 infiltration,	 pannus	 formation	 and	 cartilage	
degradation	 (Storgard	et	 al.	 1999).	 For	 these	 reasons,	 in	order	 to	 reduce	neoangiogenesis,	
drugs	able	to	block	this	integrin	were	developed	but	they	were	ineffective	in	human	clinical	
trials	(Lainer-Carr	&	Brahn	2007).	Although,	due	to	its	overexpression	in	blood	vessels	of	tumor	











arthritis,	 each	model	 shows	peculiar	 features.	 Indeed,	 the	model	 to	 use	 should	 be	 chosen	
according	 to	 the	aim	of	 the	 research	 taking	 into	account	 its	 pros	 and	 cons.	Moreover,	 the	
results	 obtained	with	 animal	models	 should	 be	 assessed	 carefully	 because	 of	 the	 intrinsic	
differences	between	human	and	other	animals	(Hu	et	al.	2013).	
1.3.1. Collagen	induced	arthritis	(CIA)	
The	 discovery	 of	 anti-collagen	 antibodies,	 that	 have	 been	 found	 in	 the	 serum	 of	 patients	
affected	by	rheumatoid	arthritis,	was	the	motivation	to	develop	an	experimental	model	based	


























First,	 animals	are	 immunized	with	 two	 intra-dermal	 injections	of	methylated	bovine	 serum	
albumin	(mBSA)	or	another	antigen,	inducing	an	immune	response	against	the	protein	with	a	
production	of	 anti-antigen	 antibodies.	 Then,	 the	 same	antigen	 is	 injected	 into	 a	 knee	 joint	
cavity	 inducing	 the	 formation	 of	 immune	 complexes	 and	 consequently	 the	 inflammation	
(Griffiths	1992).	Three	days	after,	the	inflammation	is	evident	due	to	the	swollen	knee	joint.	
The	 inflammatory	 process	 reaches	 the	 highest	 degree	 after	 one	 week,	 when	 synovial	






















called	 “adjuvant	 induced	 arthritis”.	 Freund’s	 adjuvant	 is	 a	mix	 of	mineral	 oil	 and	 antigens,	
which	acts	as	a	booster	of	the	immune	response.	This	model	has	been	used	to	investigate	the	
role	 of	 T-cells,	 which	 are	 stimulated	 by	 the	 adjuvant	 injection	 to	 start	 the	 inflammatory	
process.	 The	 rat	 strain	 is	 important	 for	 the	development	of	 inflammation,	 indeed	 Lewis	or	








complexity	 of	 the	 disease	 and	 it	 is	 not	 suitable	 for	 long-term	 studies.	 Another	 model	 to	
mention	is	the	collagen	antibody-induced	arthritis	(CAIA).	This	model	is	similar	to	CIA,	and	is	






The	 comprehension	 of	 new	 molecular	 mechanisms	 underlies	 rheumatoid	 arthritis	 has	
improved	the	diagnosis	and	therapy	of	the	disease.	Surely,	an	early	diagnosis	is	essential	for	a	
successful	 therapy.	 Indeed,	 treat	 the	 disease	 as	 early	 as	 possible	 allows	 avoiding	 cartilage	























modifying	antirheumatic	drugs	 (DMARDs).	 Indeed,	drugs	belonging	 to	 this	class	are	able	 to	
reduce	 structural	 damage	 while	 non-steroidal	 anti-inflammatory	 drugs	 (NSAIDs)	 do	 not	
interfere	with	the	joint	damage.	However,	these	are	used	to	reduce	joint	pain	and	stiffness.	By	






are	 extensively	 used	 to	 treat	 RA	 and	 according	 to	 EULAR	 recommendation	 the	 treatment	
should	start	with	one	of	these	drugs	in	combination	with	low	dose	of	glucocorticoids.	However,	
methotrexate	is	considered	the	anchor	drug	because	it	shows	a	superior	outcome	compared	
with	other	DMARDs	and	because	 it	 has	been	demonstrated	 that	methotrexate	has	 a	 safer	
profile	that	other	synthetic	DMARDs,	probably	because	of	its	low	dose	of	administration.		
1.4.2. Methotrexate	
	Methotrexate	 (MTX)	 is	 a	 chemical	 compound	 analog	 to	 folic	 acid	 capable	 to	 inhibit	 the	
dihydrofolate	 reductase	 (DHFR),	 an	 enzyme	 essential	 for	 the	 synthesis	 of	 tetrahydrofolate	






Initially,	 the	 therapeutic	 effect	 of	MTX	 on	 rheumatoid	 arthritis	was	 attributed	 solely	 to	 its	
ability	 to	 reduce	 the	 number	 of	 high	 proliferative	 cells,	 such	 as	 lymphocytes	 and	 other	
inflammatory	cells	responsible	for	the	inflammation.	Other	mechanisms	of	action	have	been	




cyclic	 adenosine	monophosphate	 (cAMP)	with	 consequent	 immunosuppression	 due	 to	 the	
reduced	production	of	pro-inflammatory	cytokines	such	as	TNF-a	and	 IL-1b.	Moreover,	 the	
activation	of	A2	 receptors	 induces	 the	production	of	anti-inflammatory	 cytokines	 like	 IL-10	
(Johnston-Cox	 et	 al.	 2012).	 Although	MTX	 is	 the	most	 effective	 drug	 compared	with	 other	






















cytokines	 such	 as	 IL-1,	 IL-6,	 IL-8	 and	 the	 growth	 factor	 GM-CSF	 (Butler	 et	 al.	 1995).	 The	
effectiveness	has	been	demonstrated	in	animal	models	of	RA	where	the	anti-TNF-a	treatment	
reduces	 paw	 swelling	 and	 histological	 severity	 (Williams	 et	 al.	 1992).	 These	 improvements	
where	 than	 confirmed	 in	 humans	 by	 several	 studies	 showing	 that	 anti-TNF-a	 inhibition	




target	one	specific	molecule,	 like	 JAK	 inhibitors,	are	 included	 in	a	new	class	of	drugs	called	












lupus-like	 reactions,	 bacterial	 infections	 and	 the	 reactivation	 of	 tuberculosis	 (TB)	 are	
associated	with	the	inhibition	of	anti-TNF-a	(Botsios	2005);	common	but	tolerable	side	effects	
like	injection-site	reaction	and	infusion	are	also	related	to	the	TNF-a	blocking	(Scott	&	Kingsley	
2006).	 Safety	 concerns	were	 reported	about	 Tofacitinib	 treatment,	where	 respiratory	 tract	
infection,	 headache,	 and	 diarrhea	were	 the	most	 common	 side	 effects	 (Fleischmann	 et	 al.	
















report	 (Dowling	 et	 al.	 2004),	 the	 European	 Science	 Foundation	 foresight	 study	 on	
nanotechnology	(Moran	2005)	and	the	Vision	paper	and	Basis	for	strategic	research	agenda	
for	Nanomedicine	by	 the	European	Technology	Platform	on	Nanomedicine	 (Boisseau	et	 al.	
2005).	 Therefore,	 according	 to	 those	 documents,	 Nanotechnology	 is	 defined	 as	 “the	
production	and	application	of	structures,	devices	and	systems	by	controlling	the	shape	and	size	
of	materials	at	nanometre	scale.	The	nanometre	scale	ranges	from	the	atomic	level	at	around	
0.2	nm	 (2	Å)	up	 to	around	1000	nm”	while	Nanomedicine	 is	defined	as	 “the	application	of	
nanotechnology	in	view	of	making	a	medical	diagnosis	or	treating	or	preventing	diseases.	 It	
exploits	the	improved	and	often	novel	physical,	chemical	and	biological	properties	of	materials	







molecules	 improving	 the	performance	of	 instruments	 such	as	 the	electron	microscopes.	 In	
conclusion,	he	foresees	“Nanotechnology”.	That	talk	 influenced	the	scientific	community	to	
challenge	 this	 research	 field	 and	 leading	 to	 the	 development	 of	 the	 scanning	 tunnelling	
microscope	 and	 the	 atomic	 force	 microscope	 (Toumey	 2009),	 breakthroughs	 which	 were	








The	 success	 of	 nanotechnology	 is	 due	 to	 the	 excellent	 and	unique	properties	 offered	 by	 a	
material	 in	 its	 nanometre	 scale.	 Nanomaterials	 find	 application	 in	 many	 different	 fields:	
electronics,	 green	 technology	 and	 alternative	 energy,	 coatings,	 industrial	 chemistry,	
nanorobotics,	cosmetics	and	biomedical.	For	examples,	silver	nanoparticles	are	widely	used	in	
disinfectants	 (Le	Ouay	&	 Stellacci	 2015)	while	 titanium	 dioxide	 and	 zinc	 oxide	 are	 used	 in	
sunscreen	and	cosmetics	(Smijs	&	Pavel	2011).	The	field	of	medicine	is	going	to	change	fast	
due	 to	 the	 influence	 of	 nanotechnology	 leading	 to	 the	 new	 field	 called	 nanomedicine.	 In	
particular,	nanoparticles	are	the	main	application	of	nanotechnology	in	the	medical	field	(Kim	
et	al.	2010).	The	success	of	nanoparticles	lies	in	the	advantages	offered	in	comparison	with	the	
free	 drugs.	 Indeed,	 drugs	 encapsulated	 in	 nanoparticles	 are	 protected	 from	 the	 biological	
environment,	 where	 enzymes	 could	 degrade	 rapidly	 drugs.	 Nanocarriers	 improve	 the	
concentration	of	the	drugs	into	the	selected	tissue	and	change	the	pharmacokinetics	of	a	drug.	




time	 diagnostic	 tracers	 and	 therapeutic	 compounds	 opening	 the	 way	 to	 the	 so	 called	
theranostics,	 or	 allow	 to	 deliver	 two	 drugs	 simultaneously,	 an	 option	 called	 combination	
therapy	 (Farokhzad	 &	 Langer	 2009).	 Several	 different	 kinds	 of	 nanocarriers	 have	 been	
produced,	 characterized	 and	 finally	 used	 for	 many	 different	 purposes:	 polymer-drug	
conjugates,	 lipid-based	 nanocarriers	 such	 as	 liposomes	 and	 micelles,	 carbon	 nanotubes,	




features	 and	 are	 used	 for	 different	 application.	Metallic	 nanoparticles	 usually	 find	medical	









the	 Kaposi	 sarcoma.	 This	 formulation	 demonstrated	 an	 improved	 circulation	 half-life	 of	
doxorubicin	and	an	increased	accumulation	in	the	tumour	tissue	(Barenholz	2012)(Gabizon	et	
al.	 2003).	 To	 this	 day,	 11	 different	 formulations	 of	 liposomes	 have	 been	 approved	 for	 the	
treatment	of	different	diseases.	They	are	spherical	vesicles	essentially	made	of	phospholipids,	
which,	due	to	their	amphiphilic	nature,	are	able	to	self-assembly	in	aqueous	solution.	The	polar	
shell	 is	made	of	a	 lipid	bilayer,	which	 is	able	 to	hold	 lipophilic	molecules	between	 the	 two	
phospholipids	bilayer.	By	contrast,	the	aqueous	core	can	be	loaded	with	hydrophilic	molecules	
(Pattni	 et	 al.	 2015).	 The	 surface	 of	 these	 structures	 can	 be	 functionalized	 with	 different	
molecules	in	order	to	target	specific	kind	of	cells	or	tissues.	Despite	the	success	of	liposomes	
based	nanocarriers	as	drug	delivery	systems,	their	use	is	still	limited	by	some	technical	reasons.	




in	 order	 to	 reduce	 contact	 with	 water	 molecules	 producing	 core-shell	 vesicles.	 These	
structures	usually	found	application	in	the	delivery	of	hydrophobic	drugs	which	can	be	loaded	
into	the	core	of	these	structures	(Xu	et	al.	2013).	
Polymer	 drug	 conjugates	 were	 first	 described	 in	 1977	 when	 researchers	 reported	 no	
immunogenicity	of	bovine	serum	albumin	(BSA)	when	conjugated	to	polyethylene	glycol	(PEG)	
(Abuchowski	et	al.	1977).	 Indeed,	because	of	 its	 low	immunogenicity,	PEG	is	the	most	used	













high	permeability	 (Palframan	et	 al.	 2009).	Another	 successful	polymer	used	as	a	 conjugate	
agent	is	hyaluronic	acid	(HA).	This	is	a	natural	polysaccharide	able	to	bind	its	receptor	CD44,	
which	has	been	found	to	be	overexpressed	in	inflamed	synovial	tissue.	For	this	reason,	HA	is	a	










Carbon	 nanotubes	 are	 cylindrical	 nanostructure	 made	 of	 benzene	 rings.	 They	 can	 have	
different	 structures	 such	 as	 single-walled	 nanotubes	 (SWNTs)	 and	multi-walled	 nanotubes	
(MWNTs).	The	latter	is	made	of	multiple	rolled	layers	of	graphene	(Eatemadi	et	al.	2014).	These	
nanostructures	have	been	exploited	mainly	for	diagnostic	purpose.	Indeed,	 issues	regarding	
their	 toxicity	 are	 still	 under	 debate	 and	 limit	 their	 prolonged	 therapeutic	 use.	 Although,	
different	 approaches	 have	 been	 used	 to	 increase	 carbon	 nanotubes	 biocompatibility	 and	
biodegradability.	 To	 this	 aim,	 chemically	 functionalised	 carbon	 nanotubes	 show	 reduced	
toxicity	and	better	degradability	due	to	the	oxidative	enzymes	(Bianco	et	al.	2011).		
Polymeric	nanoparticles	(NPs)	represent	another	class	of	successful	nanocarriers,	which	has	
been	 used	 in	 medical	 application	 both	 for	 diagnostic	 and	 therapeutic	 purposes.	 They	 are	
composed	 of	 block	 copolymers	with	 different	 hydrophilicity,	 length	 and	molecular	weight,	
which	spontaneously	assembles	into	a	core-shell	structure	in	an	aqueous	environment.	High	
amounts	 of	 therapeutics	 can	 be	 loaded	 into	 the	 core	 of	 these	 structures	 and,	 due	 to	 the	
hydrophilic	 shell,	 encapsulated	 drugs	 are	 protected	 from	 the	 external	 environment	 (Hu	 &	
Zhang	2012).	 Initially,	polymeric	nanoparticles	were	mainly	produced	by	non-biodegradable	
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and	 gelatine	 (Banik	 et	 al.	 2016).	 PLGA	 is	 one	 of	 the	 most	 used	 polymer	 due	 to	 its	
biodegradability.	It	is	hydrolysed	in	two	monomers,	one	of	lactic	acid	and	one	of	glycolic	acid	
which	 are	 both	 non-toxic	 molecules	 for	 the	 human	 body.	 In	 the	 same	 way	 PLA	 is	 a	
biocompatible	and	a	biodegradable	polymer	and	it	is	metabolized	in	monomeric	units	of	lactic	
acid,	which	is	a	natural	intermediate	of	anaerobic	respiration,	showing	very	poor	toxicity.	No	
toxicity	 was	 reported	 also	 for	 PCL	 which	 is	 degraded	 by	 hydrolysis	 of	 its	 ester	 linkages	













the	 bloodstream.	 This	 route	 showed	 a	 slow	 rate	 of	 adsorption	 and	 only	 low	 amount	 of	
nanoparticles	reach	the	target	tissue.	By	contrast,	intravenously	administrated	nanoparticles	
showed	 100%	 of	 bioavailability	 and	 a	 fast	 biodistribution	 (Simon	 &	 Sabliov	 2014).	











arrive	 in	 the	 target	 tissue.	 The	 process	 of	 opsonisation	 includes	 the	 adsorption	 of	 plasma	
proteins,	 serum	 albumin,	 immunoglobulins	 and	 complement	 proteins	 on	 the	 surface	 of	
nanoparticles.	These	proteins	form	the	so	called	“protein	corona”,	which	is	responsible	of	a	
rapid	clearance,	hindrance	of	targeting	capacity,	and	induction	of	toxicity	(Nguyen	&	Lee	2017).	




different	 factors	 such	 as	 surface	 charge,	 hydrophobicity,	 nanoparticles	 size	 and	 functional	
groups	on	the	shell.	The	best	strategy	to	design	“stealth”	nanoparticles	is	to	cover	the	surface	
with	 non-immunogenic	 and	 hydrophilic	molecules	 able	 to	mask	 the	 hydrophobicity	 of	 the	





circulation	 time	 of	 nanoparticles.	 In	 general,	 long	 chain	 of	 PEG	 (20-50	 kDa)	 are	 used	 in	
conjugation	with	small	protein	thus	preventing	renal	excretion,	while	short	PEG	chains	(3-10	









red	 blood	 cells	 (Hu	 et	 al.	 2011)	 showing	 an	 increased	 circulation	 time.	 Another	 important	
characteristic	 is	 the	 dimension	 of	 the	 nanoparticles.	 Indeed,	 nanoparticles,	 in	 order	 to	 be	
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mechanism	 (Champion	&	Mitragotri	 2006).	 Another	 endocytic	 pathway	 able	 to	 internalize	
particles	with	a	big	diameter	is	called	macropinocytosis.	Through	this	pathway,	it	is	possible	to	
internalized	particles	with	a	diameter	between	0.5	and	10	µm.	Instead,	smaller	particles	with	
a	 diameter	 of	~120	 nm	 are	 internalized	 through	 the	 clathrin-mediated	 endocytosis	 (CME).	
Many	proteins	participate	in	the	formation	of	CME	vesicles,	in	particular	clathrin,	which	coats	




enhanced	 internalization	 via	 CME	 (Yameen	 et	 al.	 2014).	 Caveolae-mediated	 endocytosis	 is	
another	route	of	internalization	which	uses	a	specific	protein	(Caveolin)	to	form	the	vesicles	
with	a	flask-shaped	structure	of	60-80	nm	(Doherty	&	McMahon	2009).	This	is	the	preferential	
route	 used	 by	 viruses	 and	 other	 pathogens	 to	 enter	 into	 host	 cells	 because	 of	 bypass	 the	
lysosomes	(Carver	&	Schnitzer	2003).	For	the	same	reason,	this	pathway	should	be	convenient	
to	delivery	DNA	or	proteins.	Moreover,	 this	pathway	 received	great	attention	because	 it	 is	
involved	in	the	trans-endothelial	pathway	thus	could	be	exploited	to	design	particles	able	to	
deliver	 its	 content	across	 the	endothelial	 tissue	 (Oh	et	al.	 2007).	However,	 are	known	 two	
alternative	mechanisms	of	internalization,	which	do	not	require	the	presence	of	coat	proteins:	







the	 movement	 and	 interaction	 are	 based	 only	 on	 the	 morphology	 and	 chemicophysical	







effect	 was	 discovered	 in	 1986	 by	 Matsumura	 Y.	 &	 Maeda	 H,	 who	 described	 the	 higher	
accumulation	of	a	drug	polymer	conjugated,	 compared	 to	 the	 free	drug,	 into	 the	 tumor	of	
tumor	bearing	mice.	This	effect	 is	 the	 result	of	 the	pathophysiologic	 features	of	 the	 tumor	




reach	 diameters	 of	 several	 µm	 (Hashizume	 et	 al.	 2000).	 In	 the	 inflamed	 tissue,	 several	










concentration	 into	 the	affected	 tissue,	 increasing	 the	effectiveness	and	often	avoiding	 side	
effects	in	healthy	tissue	(Maeda	et	al.	2013).	It	is	known	that	small	particles	are	able	to	quickly	
reach	and	diffuse	in	the	target	tissue,	but	their	retention	would	be	low	and	clearance	would	
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region.	 In	 the	 variable	 domain	 three	 hypervariable	 loops	 are	 responsible	 for	 the	 antigen	
identification,	 called	 complementarity	 determining	 region	 (CDR)	 (Kim	 et	 al.	 2005).	 Three	







produced	by	recombinant	 technology.	 Indeed,	 fundamental	were	the	studies	conducted	by	
Kohler	and	Milstein	in	1975	(Kohler	&	Milstein	1975).	They	find	a	way	to	immortalize	B	cell	






(Schroff	 et	 al.	 1985)(LoBuglio	 et	 al.	 1989).	 However,	 improvement	 of	 molecular	 biology	
technique	 allows	 researchers	 to	 reduce	 the	 murine	 component	 in	 favor	 of	 the	 human	
component,	 generating	 different	 kinds	 of	 antibodies	 such	 as	 chimeric,	 humanized	 or	 fully	
human.	 Most	 successful	 engineered	 antibodies	 used	 are:	 the	 scFv	 (single	 chain	 fragment	
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For	 this	 reason,	 it	would	be	of	great	 interest	 to	develop	new	therapeutics	able	 to	 increase	
imaging	sensitivity	highlighting	synovial	inflammation,	cartilage	and	bone	erosions	maintaining	
low	toxicity	and	invasiveness,	possibly	developing	an	approach	that	allows	the	diagnosis	with	
biocompatible	 materials,	 suitable	 for	 different	 imaging	 techniques	 such	 as	 radiography,	
ultrasounds	and	magnetic	resonance	imaging.		
	
Nanotechnologies,	 particularly	 nanoparticles,	 have	 peculiar	 characteristics	 able	 to	 satisfy	
needs	 described	 above.	 In	 fact,	 nanoparticles	 can	 be	 functionalized	 with	 antibodies	 and	
peptides	that	specifically	target	tissues	or	cells,	allowing	the	delivery	of	a	considerable	amount	
of	their	payloads	(diagnostic	tracer	or	drugs).	This	strategy	should	increase	the	concentration	




of	 this	antibody	 (Macor	et	al.	2012).	This	 strategy	demonstrated	 that	 the	 targeted	peptide	





As	 a	matter	 of	 fact,	 neoangiogenesis	 is	 a	 key	 process	 in	 the	 development	 of	 RA	with	 the	
involvement	of	adhesion	molecules,	cytokines	and	chemokines,	regulating	the	inflammatory	









to	 demonstrate	 in	 vivo,	 using	 animal	 models	 of	 rheumatoid	 arthritis,	 that	 targeted	
nanoparticles	(tBNPs),	compared	to	untargeted	nanoparticles	(BNPs),	are	able	to	specifically	
target	the	inflamed	synovial	tissues.		






















(Ethylene	diamine	 tetra	acetic	acid)	 (Sigma)	and	 resuspended	with	15mL	ProCHO5	 (Lonza),	
penicillin	10U/mL	(Sigma),	streptomycin	1μg/mL	(Sigma),	L-glutamine	2mM	(Sigma),	FBS	10%	











been	washed	with	 the	 same	equilibrating	 buffer	 and	 finally,	 the	 target	molecule	 has	 been	
eluted	using	0.1	M	sodium	citrate	buffer	pH	3.0	(elution	buffer).	Fractions	of	1.5mL	have	been	
collected	 and	 quickly	 equilibrated	with	 300μL	 1	M	 Tris-HCl	 pH	 9.0	 (neutralizing	 buffer)	 to	








gels	 were	 characterized	 by	 stacking	 4%	 and	 resolving	 10%	 acrylamide	 concentration.	 In	
particular,	the	stacking	was	made	with	Acrylamide/Bis-acrylamide	30%	solution	(Sigma),	Tris-
HCl	 130mM	 pH	 6.8,	 SDS	 0,1%,	 Ammonium	 persulfate	 0,1%	 and	 TEMED	








the	 current	 has	 been	 increased	 to	 20mA.	 Proteins	 separated	 by	 SDS	 page	 have	 been	
transferred	to	nitrocellulose	membrane	(GE	Healthcare,	Amersham	UK)	by	Western	blot	using	
a	Mini	Trans-Blot®	Module,	Bio-rad.	The	transfer	has	been	performed	at	3.5mA	cm2	for	45’	in	






washed	 three	 times	with	wash	 buffer	 and	 incubated	 30’	 RT	 in	 agitation	with	 Streptavidin-
alkaline	phosphatase	(Sigma)	diluted	1:2000	in	diluent	buffer.	Finally,	the	membrane	has	been	
washed	 three	 times	 and	 developed	 with	 0,3	 mg/ml	 of	 BCIP	 (5-Bromo-4-Chloro-3-Indolyl-
phosphate,	 Sigma)	 and	 0,6mg/ml	 of	 NBT	 (Nitro	 Blue	 Tetrazolium,	 Sigma)	 in	 alkaline	
phosphatase	buffer	(Tris-HCl	100mM,	NaCl	0,1M,	MgCl2	5mM,	pH	9.6).		
3.4. Nanoparticles	production	
In	 collaboration	 with	 Prof.	 Luis	 Nunez	 founder	 of	 BioTarget,	 company	 based	 in	 Chicago,	












Nanoparticles	 produced	 have	 been	 characterized	 by	 Dynamic	 light	 scattering	 (DLS).	 The	
hydrodynamic	diameter	distribution	has	been	measured	using	a	Malvern	Nano	ZS	instrument	
(Malvern	Instruments,	Ltd,	Malvern,	UK).	Then,	nanoparticles	diluted	1:100	in	ultrapure	H2O	
have	 been	 analyzed	 by	 Malvern	 NanoSight	 LM10.	 Through	 this	 technique	 diameter	 and	
number	of	nanoparticles	have	been	determined.	For	transmission	electron	microscopy	(TEM)	
analysis,	 nanoparticles	 have	 been	 diluted	 1:50	 in	 ultrapure	 H2O	 and	 then	 a	 drop	 of	
nanoparticles’	solution	have	been	deposited	on	a	carbon	foil	supported	on	copper	microgrids.	
Images	have	been	acquired	by	Philips	CM100	TE	microscope	(Philips	Research,	Eindhoven,	The	







Modified	 Eagle's	 Medium	 (DMEM)	 supplemented	 with	 penicillin	 10U/mL	 (Sigma),	
streptomycin	1μg/mL	(Sigma),	L-glutamine	2mM	(Sigma)	and	FBS	10%.	After	cells	adhered	to	
the	wells,	 different	 amounts	 of	 nanoparticles	 have	 been	 incubated	 for	 48h.	 Then,	 20µL	 of	











[2mg/mL]	 of	 nanoparticles	 have	 been	 placed	 in	 a	 dialysis	 device	 for	 small	 volumes	with	 a	





quantify	 the	 dialysis	 release	 of	 200µL	 of	 non-encapsulated	MTX	 [2mg/mL].	 150µL	 of	 each	







order	 to	 be	 detectable	 with	 several	 techniques.	 In	 particular,	 Fluorescein	 Isothiocyanate	









step	with	 a	 dialysis	 performed	O/N	 at	 4°C	 using	 dialysis	 tubes	with	 a	MWCO	 of	 12.4	 kDa	




nanoparticles	and	 the	 targeted	molecule.	First,	 1mg	of	nanoparticles	or	 targeting	molecule	
have	 been	 resuspended	 in	 1mL	 of	 sodium	 carbonate	 buffer	 pH	 9.3,	 respectively	 by	
centrifugation	 and	 by	 dialysis	 as	 described	 for	 FITC	 labeling.	 Then,	 the	 solutions	 with	















Ethanol	 (2’),	 one	 in	 80%	 Ethanol	 (2’)and	 one	 in	 70%	 Ethanol	 (2’).	 Then,	 slides	 have	 been	






















Co-staining	have	been	performed	with	 the	 target	molecule	 already	 conjugated	 to	Cy5.5	or	
































have	 been	 mounted	 with	 Mowiol	 anti-fade	 medium.	 Sometimes,	 a	 secondary	 antibody	





FITC.	 Otherwise,	 in	 order	 to	 detect	 the	 targeting	molecule,	 a	mouse	 anti-SV5	 (homemade	
antibody	used	1:200	in	the	diluent	buffer)	able	to	bind	the	tag	sequence	SV5	present	into	the	
targeting	molecule	have	been	used.	Finally,	a	goat	anti-mouse	Alexa	Fluor	488	(Thermo	Fisher)	




































• Nikon	 Eclipse	 Ti-E	 Live	 Cell	 Imaging	 System	 (Nikon)	 equipped	 with	 a	 Nikon	 DS-Qi2	





























and	 tBNPs-FITC,	normalized	by	 fluorescence	 intensity	by	spectrophotometric	method,	have	
been	 incubated	 with	 cells	 for	 1h	 at	 37°C	 with	 30%	 of	 FBS	 in	 PBS.	 In	 order	 to	 remove	
nanoparticles	which	do	not	bind	cells,	wells	have	been	washed	three	times	with	PBS.	Finally,	













(approval	 n°	 220/2013-B)	 and	by	 the	ethics	 committee	of	 the	University	of	 Trieste.	All	 the	
experimental	 procedures	 have	 been	 conducted	 under	 total	 anesthesia	 by	 intraperitoneal	
injection	of	Zoletil	(25mg/	Kg)	and	Xylazine	(7.5mg/	Kg).	The	immunization	has	been	performed	



































































have	 been	 previously	 fixed	 in	 10%	neutral	 buffered	 formalin	 (BioOptica)	 for	 24h	 and	 then	
decalcifying	for	24h	with	Decalcifying	Solution-Lite	(Sigma).		
Therapeutic	efficacy	
Five	 different	 groups	 of	 mice	 have	 been	 used	 to	 assess	 the	 therapeutic	 efficacy	 of	 MTX	











In	order	 to	evaluate	 the	histological	 scores	of	 the	paws	collected	 in	CIA	mice,	Hematoxylin	
Eosin	staining	have	been	performed	in	these	samples.	The	specimens	have	been	fixed	in	10%	
buffered	 formalin	 solution	and	embedded	 in	paraffin.	 Four	micrometer-thick	 sections	have	
been	dewaxed	by	immersion	in	xylene	twice	for	5’	followed	by	one	wash	in	100%	ethanol	(2’),	
one	in	96%	ethanol	(2’),	one	in	80%	ethanol	(2’)and	one	in	70%	ethanol	(2’).	Afterward,	slides	




























develop	 the	 reaction.	 The	plate	 has	 been	measured	 at	 405	nm	by	 Infinite	M200	Pro	plate	
reader	(Tecan).	
3.17. ELISA	rat	anti-mBSA	antibodies	
In	 order	 to	 verify	 that	 rats	 enrolled	 in	 the	 study	 developed	 an	 immune	 response	 against	
methylated	bovine	serum	albumin	(mBSA)	an	ELISA	test	has	been	used.	A	solution	of	5µg/	mL	
(100µL/	well)	of	mBSA	(Sigma)	in	carbonate	buffer	0,1	M	pH	9	have	been	used	O/N	at	4°C	as	









buffer	and	 incubated	 for	1h	at	RT.	After	 three	more	washes	with	wash	buffer,	 streptavidin	






In	 order	 to	 measure	 the	 number	 of	 PMN	 leukocytes	 in	 synovial	 fluids	 of	 AIA	 rats,	 the	
myeloperoxidase	activity	has	been	measured.	For	 this	purpose,	a	 standard	curve	with	 rat’s	
PMN	with	 known	 concentration	 (500000cells/mL)	 has	 been	 prepared.	Hundred	μL	 of	 each	
sample	has	been	loaded	in	well	of	a	96	well	plate	polystyrene	flat	bottom	(Costar)	and	then,	
100	μL	of	peroxidase	substrate	TMB	(Sigma)	has	been	added	to	each	well.	The	colorimetric	


























vector	pcDNA3.1/Hygro+;	 it	 contains	 the	 sequence	of	 a	 non-correlated	 ScFv,	 the	 sequence	
coding	 for	 the	 hinge-CH2-CH3	 of	 the	 rat	 IgG2b,	 the	 sequence	 for	 the	 SV5	 tag	 (used	 for	
detection)	and	the	sequence	for	the	synovial	peptide.	In	order	to	obtain	a	stable	clone	able	to	
produce	high	amount	of	the	targeting	molecule,	the	vector	coding	for	its	sequence,	previously	
checked	 by	 DNA	 sequencing,	 has	 been	 transfected	 in	mammalian	 cells	 of	 Chines	 Hamster	
Ovary	(CHO).	The	3D	structure	of	the	targeting	molecule	has	been	predicted	through	the	web	
server	Phyre2	(Kelley	et	al.	2015),	aiming	to	understand	the	peptide’s	orientation	in	the	3D	
space	 and	whether	 the	 peptide	 could	 be	masked	 during	 the	 folding	 of	 the	 final	 structure	
(Figure	 9	 C).	 The	 prediction	 is	 performed	 through	 a	 combination	 of	 multiple	 template	
modelling	 and	 ab-initio	 folding	 simulation.	 The	 94%	 of	 residues	 of	 the	 final	 3D	 structure	
reported	 in	 the	 figure	9	C	have	been	modelled	with	a	confidence	higher	 than	90%	and	the	
peptide	(Figure	9	C	red	box)	appears	available	to	interact	with	its	counterpart.		
The	 targeting	 molecules	 have	 been	 produced	 and	 purified	 by	 affinity	 chromatography	
exploiting	the	binding	between	the	Fc	and	the	protein	A.	The	molecular	weight	and	the	quality	
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In	 order	 to	 better	 identify	 the	 protein	 bound	 by	 the	 targeting	 molecule,	 an	 immuno-
precipitation	followed	by	mass	spectrometry	analysis	has	been	conducted;	in	particular,	the	
targeting	 molecules	 have	 been	 coupled	 to	 Sepharose	 beads	 and	 a	 lysate	 of	 EA.hy	 926	
endothelial	cell	 line	has	been	used	as	 loading	material.	A	ScFv-Fc	fused	with	a	RGD	peptide	
coupled	to	Sepharose	has	been	used	as	the	control.	Several	proteins	differentially	bound	by	
the	 synovial	 peptide	 have	 been	 identified,	 however,	 any	 of	 them	 could	 be	 reasonably	
associated	with	a	surface	protein	of	endothelial	cells.	Indeed,	most	of	the	proteins	identified	
comes	from	the	inner	part	of	the	cells,	so	are	in	contrast	with	our	immunofluorescence	findings	
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According	 to	 the	 recent	 literature,	 already	 discussed	 in	 the	 introduction	 of	 this	 work,	
nanoparticles	can	be	designed	in	order	to	increase	specificity	for	a	target	tissue	reducing	doses	
of	 drugs	 and	 their	 consequent	 toxicity.	 Following	 the	 rationale	 of	 the	 project,	 core-shell	
biodegradable	 polymeric	 nanoparticles	 made	 of	 COOH-poly(ethylene	 glycol)-b-polylactide	
(PEG-b-PLA)	 and	Poly(caprolactone)-COOH	 (PCL)	were	 produced	 in	 collaboration	with	 Prof.	
Luis	 Núñez	 founder	 of	 BioTarget,	 a	 company	 based	 in	 Chicago.	 Due	 to	 their	 patented	
technology	and	methodology	(number	US20080187487	A1)	based	on	a	electrohydrodynamic	
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low	 reliability,	 5	 residues	 out	 of	 9	 are	 identical	 to	 those	 of	 E3	 ubiquitin-protein	 ligase,	 in	





purple,	while	 the	guanidinium	group	of	Arg	 residues	 are	 shown	 in	pink.	 In	 the	3D	models,	
reported	from	different	viewpoints,	is	possible	to	appreciate	many	free	amino	groups	spreads	
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Domain/Fragment Residues Template Technique Reliability 
scFv-heavy chain 1-121 4nyl(A) Transfer of coordinates high 
linker 122-137 - Not modeled - 
scFv-light chain 138-244 4nyl(B) Transfer of coordinates high 
hinge 245-261 1IGT Comparative & ab initio modeling (Modeller) medium/low 
Fc-CH2 262-370 1IGT Comparative modeling (Modeller) high 
Fc-CH3 371-472 1IGT Comparative modeling (Modeller) high 
Fc-tail 473-478 - Ab initio modeling (Modeller) low/no 
SV5 479-492 2B5L(C) Transfer of coordinates medium 
Targeting peptide 492-501 4GY5 










fundamental	 to	 transfer	 this	 technology	 in	a	 clinical	 context.	The	negative	charge	prevents	
undesired	 interaction	 with	 the	 MPS	 and	 shows	 low	 toxicity	 than	 positively	 charged	
nanoparticles.	Usually,	the	charge	is	expressed	as	Zeta	potential	(ζ),	which	reflex	the	charge	on	
the	nanoparticles’	surface.	The	diameter	plays	an	important	role	in	the	clearance,	circulation	








9.6mV	 (Figure	 13	 A).	 Data	 obtained	 by	 DLS	 have	 been	 confirmed	 by	 nanoparticle	 tracking	
analysis	(NTA),	a	technique	similar	to	the	DLS,	which	give	us	additional	information	regarding	
the	number	of	 nanoparticles	 in	 solution	 (Figure	 13	B).	 Indeed,	 through	 this	 technique,	 the	
average	 diameter	 has	 been	 170nm	 while	 the	 PDI	 about	 0.2.	 Concerning	 the	 number	 of	
nanoparticles	in	solution,	the	average	concentration	has	been	3	x	1010particles/	mL.	Moreover,	
information	 regarding	 the	morphology	 and	 the	 state	 of	 aggregation	 has	 been	 collected	 by	
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As	 expected,	 MTX	 encapsulated	 into	 nanoparticles	 had	 a	 superior	 cytotoxicity	 against	









release,	 a	 plateau	 is	 reached	 after	 5	 hours	 demonstrating	 that	 50%	 of	MTX	 is	 still	 stable	
encapsulated	 in	 the	 core	 of	 the	 nanoparticles	 for	 at	 least	 24h.	 This	 result	 suggests	 that	
nanoparticles,	once	injected	and	reached	the	target,	may	release	50%	of	the	drug	over	a	period	
longer	 than	 24h.	 The	 initial	 fast	 release	 is	 known	 as	 “burst	 release”,	 a	 phenomenon	
characterizing	 drug	 delivery	 systems.	 Indeed,	 numbers	 of	 papers	 have	 been	 published	 to	
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fluorescence)	 if	 compared	 with	 the	 healthy	 synovial	 tissue.	 Later,	 nanoparticles	 coupled	
with/out	the	target	molecules	and	labelled	with	FITC	have	been	incubated	with	inflamed	and	
healthy	 synovial	 tissue	 (Figure	 15	 B).	 A	 higher	 number	 of	 green	 spots,	 in	 other	 words	
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the	use	of	 fixative	solution	and	 the	use	of	detergents,	which	can	be	 incompatible	with	 the	
stability	of	the	nanoparticles.	Thus,	in	order	to	improve	our	knowledge	about	the	targeting	and	
the	 internalization	 into	 endothelial	 cells,	 in	 vitro	 experiments	 have	 been	 conducted	 with	













Moreover,	 this	 method	 allows	 to	 quantify	 the	 percentage	 of	 internalised	 nanoparticles.	




































































































































































with	 internalized	nanoparticles	 typically	 have	positive	 scores	while	 cells	with	 no	 internalization	have	negative	 scores.	 (D)	
Representative	images	acquired	during	the	analysis	of	two	cells	positive	for	FITC,	one	with	tBNPs-FITC	and	one	with	BNPs-
FITC.	Scale	bar	20µm.	(E)	The	graph	summarises	percentage	of	cells	positive	for	FITC	when	incubated	with	BNPs-FITC	or	tBNPs-









knee,	 nanoparticles	 have	 been	 injected	 and	 then	 followed	 for	 23	 days	 (Figure	 17	 A).	 The	
animals,	 analysed	 following	 Cy5.5	 by	 near	 infrared	 optical	 imaging,	 clearly	 show	 a	 higher	
accumulation	of	fluorescence	in	the	right	knee	of	the	animals	receiving	tBNPs-Cy5.5	compared	
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assessed	 in	order	 to	associate	 the	 fluorescence	with	disease	progression.	 It	 is	 important	 to	













probably	 due	 to	 the	 clearance	 of	 the	 excess	 of	 nanoparticles.	 Finally,	 the	 fluorescence	
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MTX	 three	 times	 per	 week	 and	 represents	 the	 positive	 control,	 adapting	 data	 present	 in	















At	 the	 end	 of	 the	 study,	 mice	 have	 been	 euthanized	 and	 paws	 have	 been	 collected	 for	
subsequent	analysis.	Indeed,	the	therapeutic	efficacy	of	the	tBNPs-MTX	compared	to	control	
and	free	MTX	have	been	validated	by	histological	analyses	(Figure	20	B).	These	images	were	
















































































































































































































































































MTX 1mg/Kg 3 x week (n=6)
MTX 3mg/Kg 1 x week (n=4)
tBNPs-MTX 1mg/Kg 1 x week (n=4)























One	 of	 the	 goals	 of	 this	 project	 is	 to	 demonstrate	 that	 same	 therapeutic	 effects	 can	 be	
obtained	using	a	lower	dose	of	drug	by	targeted	approaches.	As	a	result,	a	lower	dose	of	the	
encapsulated	drug	and	a	different	 route	of	elimination	 (liver-bile-intestine)	 should	coincide	
with	lower	side	effects.	One	of	the	parameters	considered	to	assess	toxicity	is	the	reduction	of	
the	 body	weight	 (Figure	 21	A).	 The	 histogram	 shows	 the	 reduction	 of	 gain	weight	 in	mice	
treated	with	MTX	3mg/	Kg	once	per	week	compared	to	control	mice	and	mice	treated	with	
both	 doses	 of	 tBNPs-MTX.	 Moreover,	 another	 parameter	 used	 to	 demonstrate	 less	 toxic	
effects	 is	based	on	blood	analysis	 (Figure	21	B-G).	Reduction	of	WBC,	RBC	and	PLT	usually	
reflect	toxic	effects	of	the	treatment.	Regarding	WBC,	mice	treated	with	1mg/	Kg	of	MTX	three	




























information	 that	 can	 be	 obtained,	 it	 is	 difficult	 to	 fully	 understand	 and	 contextualize	 their	
variation	in	the	inflammatory	cells	network	happened	in	this	chronic	model	of	RA.	Moreover,	
these	profiles	concern	the	systemic	cytokines	and	do	not	perfectly	reflect	cytokines	levels	in	
the	 inflamed	 synovia,	where	 the	 local	 profiles	 could	 be	 different.	Moreover,	 cytokines	 act	
through	their	receptors,	which	in	turn	can	be	upregulated	or	downregulated	to	compensate	
cytokines	 low	 expression	 or	 overexpression.	 However,	 cytokines	 quantification	 gives	 a	
reasonable	idea	of	the	inflammatory	landscape	and	should	be	used	as	additional	information	
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targeting	strategy,	 thus	a	higher	concentration	of	MTX	 into	 the	synovial	 tissue,	or	whether	
there	 was	 a	 contribution	 of	 a	 different	 mechanism	 of	 action	 of	 the	 drug	 encapsulated	 in	
targeted	nanoparticles.	
In	order	to	dissect	the	mechanism	of	action	of	tBNPs	loaded	with	MTX,	the	treatment	of	the	
AIA	model	has	been	 taken	 in	 consideration	because	 it	 is	 known	 in	 the	 literature	 to	be	not	
treatable	with	free	MTX	(Williams	et	al.	1996)(Williams	2001).	In	fact,	in	this	acute	model,	the	
inflammatory	damage	is	mainly	caused	by	the	production	of	immune	complexes	in	the	joint	




treated	 with	 MTX	 1	 mg/	 Kg/	 day	 and	 5	 rats	 were	 treated	 with	 tBNPs-MTX	 1mg/Kg.	 The	
treatments	 started	 simultaneously	with	 the	 induction	of	 the	 inflammation.	The	 fourth	day,	























white	blood	cells	has	been	 reported	 in	 the	group	of	 rats	 treated	with	 free	MTX,	while	 rats	
treated	with	the	same	dose	of	tBNPs-MTX	showed	similar	WBC	than	control	rats.	This	result	
highlights	 the	 fact	 that	 in	 our	 approach,	MTX	 remains	mainly	 encapsulated	 into	 tBNPs,	 it	
performs	its	activity	directly	in	the	inflamed	synovia,	decreasing	side	effects	associated	with	a	
non-specific	delivery.	Although	the	total	number	of	WBCs	remained	unchanged	in	rats	treated	
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(as	 a	 negative	 control),	 rats	 treated	with	both	 tBNPs-MTX	and	 free	MTX.	 It	 is	 evident	 that	
synovial	tissue	of	tBNPs-MTX	treated	rats	shows	a	reduced	vWF	staining,	so	a	reduced	number	
of	blood	vessels,	compared	with	synovial	tissues	of	control	rats	or	rats	treated	with	free	MTX.	
Fluorescence	 intensity	 of	 vWF	 of	 the	 rats	 enrolled	 in	 the	 study	 have	 been	 quantified	 and	
summarized	 in	 the	 graph	 of	 the	 figure	 25	 B.	 The	 graph	 confirms	 a	 reduced	 vWF	 staining	






























inflammation	of	 the	 synovial	membrane,	which	 leads	 to	 a	 condition	 of	 disability	 and	pain.	






treatment	 because	 of	 inefficacy	 or	 side	 effects	 such	 as	 liver	 toxicity	 and	 bone	 marrow	


































through	 the	 synovial	 peptide	will	 represent	 a	 potential	 probe	 for	 functional	 imaging	 using	
ultrasound,	as	well	as	 targeted	nanoparticles	 loaded	with	contrast	agents	may	be	useful	 in	
NMR	o	x-ray-based	approaches.		











per	week.	Moreover,	 the	 therapeutic	effects	were	also	associated	with	a	 safe	 toxicological	
profile.	
Part	of	this	work	has	been	dedicated	to	identifying	the	counterpart	of	the	targeting	molecule.	
Indeed,	 from	 the	 literature,	 it	 is	 known	 that	 the	 synovial	 homing	 peptide	 binds	 the	
microvasculature	 of	 the	 inflamed	 synovial	 tissue,	 although	 the	 bound	molecule	 is	 not	 yet	
recognized.	Co-staining	immunofluorescence	performed	with	the	target	molecule	and	markers	












in	 synovial	microenvironment	 brings	 to	 a	 reduction	 of	 the	 inflammatory	 process.	 This	was	
particularly	 evident	 in	 an	 AIA	 rat	 model,	 where	 free	 MTX	 was	 ineffective.	 However,	 the	
formation	of	new	vessels	in	synovial	tissue	was	reduced	using	tBNP-MTX,	preventing	the	onset	
of	the	pathology.		
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